Mel B Feany

List of Publications by Year
in descending order

77 papers	13,671 citations	57681 46 h-index	84171 75 g-index
84 all docs	84 docs citations	84 times ranked	15438 citing authors

#	Article	IF	Citations
1	Case Study 1: A 55-Year-Old Woman With Progressive Cognitive, Perceptual, and Motor Impairments. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 8-15.	0.9	2
2	Anastasis Drives Senescence and Non-Cell Autonomous Neurodegeneration in the Astrogliopathy Alexander Disease. Journal of Neuroscience, 2022, 42, 2584-2597.	1.7	2
3	Î±-synuclein impairs autophagosome maturation through abnormal actin stabilization. PLoS Genetics, 2021, 17, e1009359.	1.5	49
4	Oligomerization of Lrrk controls actin severing and Î±-synuclein neurotoxicity in vivo. Molecular Neurodegeneration, 2021, 16, 33.	4.4	6
5	Precision Medicine on the Fly: Using <i>Drosophila</i> to Decipher Gene-Environment Interactions in Parkinsonâ€™s Disease. Toxicological Sciences, 2021, 182, 159-167.	1.4	8
6	Elevated Oxidative Stress and DNA Damage in Cortical Neurons of Chemotherapy Patients. Journal of Neuropathology and Experimental Neurology, 2021, 80, 705-712.	0.9	9
7	Parkinson's disease risk genes act in glia to control neuronal Î±-synuclein toxicity. Neurobiology of Disease, 2021, 159, 105482.	2.1	19
8	Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment. Science Translational Medicine, 2021, 13, eabg4711.	5.8	21
9	Iatrogenic Neuropathology of Systemic Therapies. Surgical Pathology Clinics, 2020, 13, 331-342.	0.7	4
10	Comparative proteomic analysis highlights metabolic dysfunction in Î±-synucleinopathy. Npj Parkinson's Disease, 2020, 6, 40.	2.5	16
11	Biotin rescues mitochondrial dysfunction and neurotoxicity in a tauopathy model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 33608-33618.	3.3	20
12	New-Onset Delusions Heralding an Underlying Neurodegenerative Condition. Journal of Clinical Psychiatry, 2020, 81, .	1.1	1
13	Glial Î±â€synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo. Glia, 2019, 67, 1933-1957.	2.5	27
14	PARP Inhibitors and Parkinsonâ€™s Disease. New England Journal of Medicine, 2019, 380, 492-494.	13.9	31
15	Development of geneâ€environment interaction model in Drosophila for neurodegenerative disease: A step towards personalized medicine. FASEB Journal, 2019, 33, 813.14.	0.2	0
16	Î±-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton. Neuron, 2018, 97, 108-124.e6.	3.8	181
17	A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations<i>In Vivo</i>. Journal of Neuroscience, 2018, 38, 108-119.	1.7	35
18	Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics. PLoS Biology, 2018, 16, e2006265.	2.6	44

#	Article	IF	Citations
19	Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease. Nature Communications, 2018, 9, 1899.	5.8	43
20	Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. Neurobiology of Disease, 2017, 106, 191-204.	2.1	28
21	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	3.9	380
22	Defective Phagocytic Corpse Processing Results in Neurodegeneration and Can Be Rescued by TORC1 Activation. Journal of Neuroscience, 2016, 36, 3170-3183.	1.7	50
23	An<i>In Vivo</i>Pharmacological Screen Identifies Cholinergic Signaling as a Therapeutic Target in Glial-Based Nervous System Disease. Journal of Neuroscience, 2016, 36, 1445-1455.	1.7	34
24	Lamin Dysfunction Mediates Neurodegeneration in Tauopathies. Current Biology, 2016, 26, 129-136.	1.8	184
25	Nitric oxide mediates glial-induced neurodegeneration in Alexander disease. Nature Communications, 2015, 6, 8966.	5.8	44
26	Connecting the dots between tau dysfunction and neurodegeneration. Trends in Cell Biology, 2015, 25, 46-53.	3.6	108
27	p53 prevents neurodegeneration by regulating synaptic genes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18055-18060.	3.3	65
28	Tau promotes neurodegeneration through global chromatin relaxation. Nature Neuroscience, 2014, 17, 357-366.	7.1	370
29	Glia are critical for the neuropathology of complex I deficiency in Drosophila. Human Molecular Genetics, 2014, 23, 4686-4692.	1.4	34
30	Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms. Human Molecular Genetics, 2014, 23, 870-877.	1.4	147
31	Why size matters â€“ balancing mitochondrial dynamics in Alzheimer's disease. Trends in Neurosciences, 2013, 36, 325-335.	4.2	150
32	Alexander Disease. Journal of Neuroscience, 2012, 32, 5017-5023.	1.7	210
33	A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging Cell, 2012, 11, 360-362.	3.0	47
34	Tau Promotes Neurodegeneration via DRP1 Mislocalization InÂVivo. Neuron, 2012, 75, 618-632.	3.8	331
35	Parkinson's Disease: Genetics and Pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 193-222.	9.6	654
36	Functional Screening of Alzheimer Pathology Genome-wide Association Signals in Drosophila. American Journal of Human Genetics, 2011, 88, 232-238.	2.6	81

#	Article	IF	Citations
37	Protein Misfolding and Oxidative Stress Promote Glial-Mediated Neurodegeneration in an Alexander Disease Model. Journal of Neuroscience, 2011, 31, 2868-2877.	1.7	67
38	Glial Fibrillary Tangles and JAK/STAT-Mediated Glial and Neuronal Cell Death in a<i>Drosophila</i>Model of Glial Tauopathy. Journal of Neuroscience, 2010, 30, 16102-16113.	1.7	64
39	Lysosomal Dysfunction Promotes Cleavage and Neurotoxicity of Tau In Vivo. PLoS Genetics, 2010, 6, e1001026.	1.5	132
40	Parkinson's disease: Insights from non-traditional model organisms. Progress in Neurobiology, 2010, 92, 558-571.	2.8	60
41	New Approaches to the Pathology and Genetics of Neurodegeneration. American Journal of Pathology, 2010, 176, 2058-2066.	1.9	15
42	The Unfolded Protein Response Protects from Tau Neurotoxicity In Vivo. PLoS ONE, 2010, 5, e13084.	1.1	80
43	Tyrosine and serine phosphorylation of Î±-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. Journal of Clinical Investigation, 2009, 119, 3257-65.	3.9	158
44	Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntingtonâ€™s disease model. DMM Disease Models and Mechanisms, 2009, 2, 247-266.	1.2	80
45	Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Molecular Brain, 2009, 2, 5.	1.3	232
46	Î±-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 515-524.	0.9	111
47	Tau Phosphorylation Sites Work in Concert to Promote Neurotoxicity In Vivo. Molecular Biology of the Cell, 2007, 18, 5060-5068.	0.9	178
48	Connecting cell-cycle activation to neurodegeneration in Drosophila. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 446-456.	1.8	24
49	Calpain-Cleavage of Î±-Synuclein. American Journal of Pathology, 2007, 170, 1725-1738.	1.9	213
50	Sirtuin 2 Inhibitors Rescue Â-Synuclein-Mediated Toxicity in Models of Parkinson's Disease. Science, 2007, 317, 516-519.	6.0	995
51	Aggregated Â-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo. Journal of Neuroscience, 2007, 27, 3338-3346.	1.7	271
52	S/P and T/P phosphorylation is critical for tau neurotoxicity inDrosophila. Journal of Neuroscience Research, 2007, 85, 1271-1278.	1.3	108
53	Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nature Cell Biology, 2007, 9, 139-148.	4.6	399
54	Oxidative stress mediates tau-induced neurodegeneration in Drosophila. Journal of Clinical Investigation, 2007, 117, 236-245.	3.9	262

#	Article	IF	Citations
55	Î±-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Human Molecular Genetics, 2006, 15, 3012-3023.	1.4	486
56	TOR-Mediated Cell-Cycle Activation Causes Neurodegeneration in a Drosophila Tauopathy Model. Current Biology, 2006, 16, 230-241.	1.8	251
57	Accelerated Accumulation of Misfolded Prion Protein and Spongiform Degeneration in a Drosophila Model of Gerstmann-Straussler-Scheinker Syndrome. Journal of Neuroscience, 2006, 26, 12408-12414.	1.7	53
58	Î±-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nature Neuroscience, 2005, 8, 657-663.	7.1	575
59	Proliferative Potential of Human Astrocytes. Journal of Neuropathology and Experimental Neurology, 2005, 64, 163-169.	0.9	51
60	Cathepsin D-deficient Drosophila recapitulate the key features of neuronal ceroid lipofuscinoses. Neurobiology of Disease, 2005, 19, 194-199.	2.1	68
61	Disease-related phenotypes in a Drosophila model of hereditary spastic paraplegia are ameliorated by treatment with vinblastine. Journal of Clinical Investigation, 2005, 115, 3026-3034.	3.9	99
62	Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Human Molecular Genetics, 2004, 13, 2011-2018.	1.4	99
63	Yeast genetics targets lipids in Parkinson's disease. Trends in Genetics, 2004, 20, 273-277.	2.9	29
64	Post-transcriptional suppression of pathogenic prion protein expression in Drosophila neurons. Journal of Neurochemistry, 2003, 85, 1614-1623.	2.1	23
65	Parkin. Neuron, 2003, 38, 13-16.	3.8	108
66	Polyglutamines Stop Traffic. Neuron, 2003, 40, 1-2.	3.8	39
67	Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Human Molecular Genetics, 2003, 12, 2457-2466.	1.4	111
68	Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4078-4083.	3.3	1,117
69	Title is missing!. Current Opinion in Neurology, 2003, 16, 443-449.	1.8	20
70	From fruit fly to bedside. Current Opinion in Neurology, 2003, 16, 443-449.	1.8	83
71	Genetic Modifiers of Tauopathy in Drosophila. Genetics, 2003, 165, 1233-1242.	1.2	237
72	Modelling neurodegenerative diseases in Drosophila: a fruitful approach?. Nature Reviews Neuroscience, 2002, 3, 237-243.	4.9	144

#	Article	IF	Citations
73	Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles. Science, 2001, 293, 711-714.	6.0	868
74	Studying Human Neurodegenerative Diseases in Flies and Worms. Journal of Neuropathology and Experimental Neurology, 2000, 59, 847-856.	0.9	34
75	A Drosophila model of Parkinson's disease. Nature, 2000, 404, 394-398.	13.7	1,927
76	Neurodegenerative disorders with extensive tau pathology: A comparative study and review. Annals of Neurology, 1996, 40, 139-148.	2.8	301
77	The synaptic vesicle protein synaptotagmin promotes formation of filopodia in fibroblasts. Nature, 1993, 364, 537-540.	13.7	63